Page 2 - Oncodesign Services News Today

This article describes the challenges in the preclinical development of therapeutic agents against lung fibrosis.

This article dives into the details behind the failure of the preclinical cancer models, reasons,consequences and potential solutions.

Toronto, ON (PRWEB) May 25, 2023 -- Protein kinases act as master regulators of multiple key processes within the cell cycle, and aberrant regulation of their

Toronto, ON (PRWEB) April 26, 2023 -- Currently, chemotherapy is the primary mode of treatment for pancreatic ductal adenocarcinoma (PDAC), a highly

Revenues and operating income in 2022 of €8.3 M (+110% vs. 2021 proforma), including revenues of €8 M, mainly driven by a €7 M milestone and a €0.5 M up-frontNet income almost at break-even (€0.2) MStrong financial visibility with a cash position of €13.4 M ensuring the development of our programs for the coming yea...

Revenues and operating income in 2022 of €8.3 M (+110% vs. 2021 proforma), including revenues of €8 M, mainly driven by a €7 M milestone and a €0.5 M up-front Net income almost at break-even

/PRNewswire/ -- The "Global Drug Discovery Services Market by Process (Target Selection, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small Molecule,...

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, follow...

As Oncodesign evolves into Oncodesign Services and begins its journey as an independent business, CEO Fabrice Viviani explains his hopes and plans for the company’s future.